Recent events, page-138

Agree 100% , Immupel was years ahead of its time, the perfect delivery mechanism for other companies to now utilise.. I was astounded at the AGM when the company stated they had been approached previously for Immupel on a commercial use and didn't pursue the deal??

LCT were ahead of Voyager (VYGR) in Phase I and II testing ,, LCT should approach this company to provide them with Immupel as a delivery mechanism ..

Seeking Alpha ran an article a couple of years back and LCT was mentioned as being advanced... beyond Voyager ,,

This is from LCT home page
LCT’s proprietary encapsulation technology, IMMUPEL™, allows cell therapies to be used without the need for co-treatment with drugs that suppress the immune system.

VYGR now have a MC of $1B so very strong financially ,, maybe LCT could sell Immupel ,, and hopefully receive a better deal than the last JV they sold for $3m,, for 2 years of analysis , tyre kicking and wages ????

Why not hold another Phase II with optimum dose and say 21 patients?? to gain recognisable significant results that don't need a statistician from Nasa to work out if it has any Patient Benefit..

LCT's History seems to be it's archilies heel ,, no commercialisation of any products and no commercial income gained in 15 years.... so LCT has been funded by Shareholders and Grants for 15 years ...

and now silence from Management...........